S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

实时更新: Eli Lilly and Co [LLY.DE]

交易所: XETRA 部门: Pharmaceuticals 工业: Drug Manufacturers—General
Upcoming Earnings Alert

2 days till quarter result
(bmo 2024-04-29)

Expected move: +/- 0.00%

最后更新时间26 Apr 2024 @ 23:35

1.97% 688.90

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:35):

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes...

Stats
今日成交量 1 991.00
平均成交量 6 522.00
市值 654.98B
EPS €0 ( 2024-02-06 )
下一个收益日期 ( €1.550 ) 2024-04-29
Last Dividend €1.130 ( 2023-08-14 )
Next Dividend €0 ( N/A )
P/E 127.57
ATR14 €0.994 (0.14%)

音量 相关性

長: -0.14 (neutral)
短: -0.44 (neutral)
Signal:(58.113) Neutral

Eli Lilly and Co 相关性

10 最正相关
10 最负相关

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Eli Lilly and Co 相关性 - 货币/商品

The country flag -0.78
( moderate negative )
The country flag -0.35
( neutral )
The country flag 0.24
( neutral )
The country flag -0.68
( moderate negative )
The country flag 0.00
( neutral )
The country flag 0.54
( weak )

Eli Lilly and Co 财务报表

Annual 2023
营收: €34.12B
毛利润: €27.04B (79.25 %)
EPS: €5.82
FY 2023
营收: €34.12B
毛利润: €27.04B (79.25 %)
EPS: €5.82
FY 2022
营收: €28.54B
毛利润: €21.91B (76.77 %)
EPS: €6.93
FY 2021
营收: €28.32B
毛利润: €21.01B (74.18 %)
EPS: €5.83

Financial Reports:

No articles found.

Eli Lilly and Co Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0.980
(N/A)
€0.980
(N/A)
€1.130
(N/A)
€1.130
(N/A)
€1.130
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Eli Lilly and Co Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 5.72 - average (57.84%) | Divividend Growth Potential Score: 6.05 - Stable (21.06%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €0.490 2009-05-13
Last Dividend €1.130 2023-08-14
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 41 --
Total Paid Out €27.35 --
Avg. Dividend % Per Year 0.00% --
Score 3.68 --
Div. Sustainability Score 5.72
Div.Growth Potential Score 6.05
Div. Directional Score 5.89 --
Next Divdend (Est)
(2024-09-05)
€1.166 Estimate 20.00 %
Dividend Stability
0.53 Average
Dividend Score
3.68
Pay Frequency
Quarterly
Yearly Payout
Year Amount Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
KTF.DE Ex Dividend Knight 2023-06-29 Quarterly 0 0.00%
2GB.DE Ex Dividend Junior 2023-06-14 Annually 0 0.00%
UDC.DE Ex Dividend Junior 2023-07-10 Annually 0 0.00%
ECGF.F Ex Dividend Junior 2023-09-14 Semi-Annually 0 0.00%
NF4.DE No Dividend Player 2023-06-27 Sporadic 0 0.00%
AEC1.DE Ex Dividend Knight 2023-07-06 Quarterly 0 0.00%
XY6.DE Ex Dividend Knight 2023-08-30 Quarterly 0 0.00%
GDX.DE Ex Dividend Knight 2023-10-05 Quarterly 0 0.00%
PHM7.DE Ex Dividend Knight 2023-09-14 Quarterly 0 0.00%
BFSA.DE Ex Dividend Junior 2023-06-16 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.1541.5006.9310.00[0 - 0.5]
returnOnAssetsTTM0.08191.2007.278.73[0 - 0.3]
returnOnEquityTTM0.4741.5005.858.77[0.1 - 1]
payoutRatioTTM0.777-1.0002.23-2.23[0 - 1]
currentRatioTTM0.9430.800-0.287-0.230[1 - 3]
quickRatioTTM0.5230.800-1.632-1.305[0.8 - 2.5]
cashRatioTTM0.1031.500-0.537-0.806[0.2 - 2]
debtRatioTTM0.394-1.5003.43-5.15[0 - 0.6]
interestCoverageTTM15.001.0005.565.56[3 - 30]
operatingCashFlowPerShareTTM4.472.008.5110.00[0 - 30]
freeCashFlowPerShareTTM-3.322.00-1.660-3.32[0 - 20]
debtEquityRatioTTM2.34-1.5000.633-0.949[0 - 2.5]
grossProfitMarginTTM0.7921.0000.1260.126[0.2 - 0.8]
operatingProfitMarginTTM0.2141.0007.737.73[0.1 - 0.6]
cashFlowToDebtRatioTTM0.1681.000-0.177-0.177[0.2 - 2]
assetTurnoverTTM0.5330.8009.787.82[0.5 - 2]
Total Score5.72

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM133.521.00010.000[1 - 100]
returnOnEquityTTM0.4742.507.338.77[0.1 - 1.5]
freeCashFlowPerShareTTM-3.322.00-1.107-3.32[0 - 30]
dividendYielPercentageTTM0.6361.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM4.472.008.5110.00[0 - 30]
payoutRatioTTM0.7771.5002.23-2.23[0 - 1]
pegRatioTTM7.681.50010.000[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1241.0009.390[0.1 - 0.5]
Total Score6.05

Eli Lilly and Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。